WO1998016523A9 - Inhibiteurs competitifs du facteur xa - Google Patents

Inhibiteurs competitifs du facteur xa

Info

Publication number
WO1998016523A9
WO1998016523A9 PCT/US1997/018291 US9718291W WO9816523A9 WO 1998016523 A9 WO1998016523 A9 WO 1998016523A9 US 9718291 W US9718291 W US 9718291W WO 9816523 A9 WO9816523 A9 WO 9816523A9
Authority
WO
WIPO (PCT)
Prior art keywords
compound
group
alkyl
aryl
integer
Prior art date
Application number
PCT/US1997/018291
Other languages
English (en)
Other versions
WO1998016523A2 (fr
WO1998016523A3 (fr
Filing date
Publication date
Application filed filed Critical
Priority to JP51845498A priority Critical patent/JP2001504810A/ja
Priority to AU49809/97A priority patent/AU720513C/en
Priority to CA002268281A priority patent/CA2268281A1/fr
Priority to EP97912697A priority patent/EP0937073A2/fr
Priority claimed from US08/948,672 external-priority patent/US6262047B1/en
Publication of WO1998016523A2 publication Critical patent/WO1998016523A2/fr
Publication of WO1998016523A3 publication Critical patent/WO1998016523A3/fr
Publication of WO1998016523A9 publication Critical patent/WO1998016523A9/fr

Links

Definitions

  • This invention relates to novel heterocyclic compounds which are potent and highly selective inhibitors of factor Xa or factor Xa when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, fVIIa, flXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin).
  • Blood coagulation protects mammalian species when the integrity of the blood vessel wall is damaged and uncontrolled loss of blood threatens survival. Coagulation, resulting in the clotting of blood is an important component of hemostasis. Under normal hemostatic circumstances, there is maintained an acute balance of clot formation and clot removal (fibrinolysis).
  • the blood coagulation cascade involves the conversion of a variety of inactive enzymes (zymogens) into active enzymes which ultimately convert the soluble plasma protein fibrinogen into an insoluble matrix of highly cross-linked fibrin.
  • thrombin A key enzyme in the coagulation cascade as well as in hemostasis, is thrombin.
  • Thrombin is intimately involved in the process of thrombus formation, but under normal circumstances can also play an anticoagulant role in hemostasis through its ability to convert protein C into activated protein C in a thrombomodulin-dependent manner.
  • Thrombin plays a central role in thrombosis through its ability to catalyze the penultimate conversion of fibrinogen into fibrin and through its potent platelet activation activity.
  • thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. 5:411-436 (1994).
  • the major classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins and coumarins).
  • thrombin i.e. heparins, low-molecular weight heparins and coumarins.
  • Thrombin is generated at the convergence of the intrinsic and extrinsic coagulation pathways by the prothrombinase complex.
  • the prothrombinase complex is formed when activated Factor X (factor Xa) and its non-enzymatic cofactor, factor Va assemble on phospholipid surfaces in a Ca" 2 - dependent fashion as reviewed by Mann, et al, "Surface-Dependent Reactions of the Vitamin -Dependent Enzymes", Blood 76:1-16 (1990).
  • Factor X Factor Xa
  • factor Va Factor Xa
  • the prothrombinase complex converts the zymogen prothrombin into the active procoagulant thrombin.
  • prothrombinase complex The location of the prothrombinase complex at the convergence of the intrinsic and extrinsic coagulation pathways, and the significant amplification of thrombin generation (393,000-fold over uncomplexed factor Xa) mediated by the complex at a limited number of targeted catalytic units present at vascular lesion sites, suggests that inhibition of thrombin generation is an ideal method to block uncontrolled procoagulant activity.
  • factor Xa appears to have a single physiologic substrate, namely prothrombin.
  • Plasma contains an endogenous inhibitor of both the factor Vila-tissue factor (TF) complex and factor Xa called tissue factor pathway inhibitor (TFPI).
  • TFPI is a unitz- type protease inhibitor with three tandem Kunitz domains.
  • TFPI inhibits the TF/fVIIa complex in a two-step mechanism which includes the initial interaction of the second Kunitz domain of TFPI with the active site of factor Xa, thereby inhibiting the proteolytic activity of factor Xa.
  • the second step involves the inhibition of the TF/fVIIa complex by formation of a quaternary complex TF/fVIIa TFPI/fXa as described by Girard, et al , "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-associated Coagulation Inhibitor", Nature 338:518-520 (1989).
  • Tick Anticoagulant Peptide is a Novel Inhibitor of Blood Coagulation Factor Xa", Science 248:593-596 (1990).
  • WO 96/18644 to Tamura, et al describes aromatic heterocyclic thrombin inhibitors.
  • WO 95/35313 to Semple, et al. pertains to 3-amino-2-oxo-l-piperidineacetic derivative thrombin inhibitors.
  • EP 0.512.831 and US Patent No. 5,281,585, both to Duggan, et al.. describe fibrinogen receptor antagonists.
  • the present invention relates to novel peptide and peptide mimetic analogs, their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives.
  • the present invention includes pharmaceutical compositions comprising a pharmaceutically effective amount of the compounds of this invention and a pharmaceutically acceptable carrier. These compositions are useful as potent and specific inhibitors of blood coagulation in mammals.
  • the invention relates to methods of using these inhibitors as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries.
  • These compositions may optionally include anticoagulants, antiplatelet agents, and thrombolytic agents.
  • the present invention provides compounds of general formula I:
  • R 1 is H, C,. 6 alkyl or C ⁇ . 3 alkylaryl
  • R 2 is H, C,. 6 alkyl, C 3 . 6 cycloalkyl, C,. 3 alkylaryl, C l . 3 alkyl-C 3 . 8 cycloalkyl or aryl and R 3 is H, C ⁇ alkyl, or R 2 and R 3 are taken together to form a carbocyclic ring;
  • m is an integer from 0-3;
  • n is an integer from 0-6;
  • p is an integer from 0-4;
  • s is an integer from 0-2;
  • q is an integer from 0-2;
  • A is selected from the group consisting of: a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;
  • R 4 ; -NR 4 R 5 is selected from the group consisting of:
  • R 4 , R 3 , R 16 and R 17 are independently selected from the group consisting of H. -OH, C
  • R 16 or R 17 to form a 5-6 membered ring and R 19 is selected from the group consisting of H, -OH, Chalky 1, aryl and or can be taken together with R 17 to form a 5-6 membered ring;
  • W is a direct link, C ⁇ . 6 alkyl, C 3-8 cycloalkyl, C ⁇ -6 alkenyl, C ⁇ . 6 alkenylaryl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S;
  • D is a direct link, -CO-, -SO 2 -, -CH 2 -, -O-CO-, -NR 15 SO 2 - or -NR l 5 -CO-, where R 15 is selected from the group consisting of H, -OH, C t . 6 alkyl. aryl and C l . 4 al ylaryl;
  • K. is selected from the group consisting of a direct link, C 3 . 8 cycloalkyl, aryl. or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, 0 and S;
  • E is selected from the group consisting of R 26 , -NR 26 R 27 ,
  • R 26 , R 27 , R 28 and R 29 are independently selected from the group consisting of H, -OH, C
  • R 30 is selected from the group consisting of H, C ⁇ . 6 alkyl, aryl and C 1- alkylaryl, or can be taken together with R 28 or R 29 to form a 5-6 membered ring;
  • R 31 is selected from the group consisting of H. C 6 alkyl, aryl and C ⁇ _ ⁇ alkylaryl, or can be taken together with R 29 to form a 5-6 membered ring; with the proviso that when E is R 26 , then K must contain at least one N atom;
  • Y is selected from the group consisting of H,
  • R 13 and R 14 are independently selected from the group consisting of H, C,. 3 alkyl and aryl; and G is -COOR 20 , -CONR 20 R 2 ⁇ -CF 3 , -CF 2 CF 3 or a group having the formula:
  • R- is selected from the group consisting of H, C,. 6 alkyl, C 2 . 6 alkenyl, C 0.6 alkylaryl C 2 -6alkenylaryl, C 0 . 6 alkylheterocyclo, C 2 . 6 alkenylheterocyclo, -CF 3 and -CF 2 CF 3 ;
  • U is -0-, -S-. -N- or -N(H)-;
  • V is -0-, -S-, -N- or -N(H)-; with the proviso that at least one of U or V is -N- or -N(H)-;
  • J is -S-, -SO-. -SO , -O- or -NR 6 -, where R 6 is H, C,. 6 alkyl or benzyl;
  • L is selected from the group consisting of:
  • R 9 and R 10 are independently selected from the group consisting of H, C l-6 alkyl, aryl, C ⁇ alkylaryl, -COOR 1 1 ,
  • R 9 and R 10 are independently selected from the group consisting of H, C ⁇ . 6 alkyl, aryl, C ⁇ -6 alkylaryl, halogen, -N0 2 , -NR"R 12 .
  • R 1 ' and R 12 are independently selected from the group consisting of
  • alkyl refers to saturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms.
  • cycloalkyl refers to a mono-, bi-. or tricyclic aliphatic ring having 3 to 12 carbon atoms, preferably 3 to 7 carbon atoms.
  • alkenyl refers to unsaturated aliphatic groups including straight-chain, branched-chain, cyclic groups, and combinations thereof, having at least one double bond and having the number of carbon atoms specified.
  • aryl refers to an unsubstituted or substituted aromatic ring(s), substituted with one, two or three substituents such as, by way of example and not limitation, C 6 alkoxy, C, .6 alkyl, C, .6 alkylamino, hydroxy, halogen, cyano (-CN), hydroxyl, mercapto, nitro (-NO 2 ), thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy, carboxamide, -NR'R", -NR'COR", -OR, -OCOR, -COOR, -CONR'R", -CF 3 , -SO 2 NR'R" and
  • aryl C ⁇ -6 alkylaryl (where the R groups can be H, C,. 6 alkyl, C ⁇ alkylaryl and aryl), including but not limited to carbocyclic aryl, heterocyclic aryl. biaryl and triaryl groups and the like, all of which may be optionally substituted.
  • Preferred aryl groups include phenyl, halophenyl, C 1-6 alkylphenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and aromatic heterocyclics or heteroaryls, the latter of which is an aryl group containing one to four heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • Aryl groups preferably have 5-14 carbon atoms making up the ring(s) structure, while heteroaryls preferably have 1-4 heteroatoms, with the remaining 4-10 atoms being carbon atoms.
  • heterocyclo and “hetero cyclic ring system” as used herein refer to any saturated or unsaturated mono- or bicyclic ring system, containing from one to four heteroatoms, selected from the group consisting of nitrogen, oxygen and sulfur.
  • a typical heterocyclic ring system will have five to ten members, 1-4 of which are heteroatoms.
  • Typical examples of monocyclic ring systems include piperidinyl, pyrrolidinyl, pyridinyl, piperidonyl, pyrrolidonyl and thiazolyl, while examples of bicyclic ring systems include benzimidazolyl, benzothiazolyl and benzoxazolyl, all of which may be substituted.
  • carrier ring refers to any saturated or unsaturated ring containing from three to six carbon atoms.
  • alkylaryl and alkenylaryl refer to an alkyl group or alkenyl group, respectively, having the number of carbon atoms designated, appended to one, two, or three aryl groups.
  • benzyl refers to -CH 2 -C 6 H 5 .
  • alkoxy refers to an alkyl linked to an oxygen atom, such as methoxy, ethoxy, and so forth.
  • halogen refers to Cl, Br, F or I substi ents.
  • direct link refers to a bond directly linking the substiments on each side of the direct link. When two adjacent substiments are defined as each being a “direct link”, it is considered to be a single bond.
  • Two substiments are "taken together to form a 5-6 membered ring” means that an ethylene or a propylene bridge, respectively, is formed between the two substiments.
  • pharmaceutically acceptable salts includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum bases, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
  • Bio property for the purposes herein means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a compound of this invention. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it. The biological properties of the compounds of the present invention can be readily characterized by the methods described in Examples 14 and 15 and by such other methods as are well known in the art.
  • Boc refers to t-butoxycarbonyl
  • BOP refers to benzotriazol-l-yloxy-tris-(dimethylamino) phosphonium hexafluorophosphate.
  • CBZ refers to benzyloxycarbonyl.
  • DIEA diisopropylethylamine
  • DMF N,N-dimethylformamide
  • Et 2 O diethyl ether
  • EtOAc ethyl acetate
  • HF hydrogen fluoride
  • HOAc acetic acid
  • Mel refers to methyl iodide.
  • MeOH refers to methanol.
  • MeSEt refers to methyl ethyl sulfide.
  • TFA trifluoroacetic acid.
  • THF tetrahydrofuran.
  • Tos refers top-toluenesulfonyl.
  • carbon atoms bonded to four non-identical substiments are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof.
  • the syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art.
  • enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art.
  • Each of the asymmetric carbon atoms when present in the compounds of this invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.
  • the final products may. in some cases, contain a small amount of diastereomeric or enantiomeric products, however these products do not affect their therapeutic or diagnostic application.
  • This replacement can be made by methods known in the art.
  • This invention relates to a new class of peptide derivatives selected from those of general formula I which are potent and specific inhibitors of Xa, their pharmaceutically acceptable compositions thereof, and the methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis:
  • R 1 is H, C ! . 6 alkyl or C,. 3 alkylaryl;
  • R 2 is H, C,. 6 alkyl, C- ⁇ cycloalkyl, C,. 3 alkylaryl, C,. 3 alkyl-C 3-8 cycloalkyl or aryl and R 3 is H, C 1-6 alkyl, or R 2 and R 3 are taken together to form a carbocyclic ring;
  • m is an integer from 0-3;
  • n is an integer from 0-6;
  • p is an integer from 0-4;
  • s is an integer from 0-2;
  • q is an integer from 0-2;
  • A is selected from the group consisting of: a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; R 4 ; -NR 4 R 5 ;
  • R 4 , R ⁇ R 16 and R 17 are independently selected from the group consisting of H,
  • R 18 is selected from the group consisting of H,
  • R 19 is selected from the group consisting of H, -OH, C ⁇ alkyl. aryl and or can be taken together with R 17 to form a 5-6 membered ring; W is a direct link, C
  • D is a direct link, -CO-, -SO , -CH 2 -, -O-CO-, -NR 15 SO 2 - or -NR 15 -CO-.
  • R 15 is selected from the group consisting of H, -OH, C ⁇ alkyl, aryl and C alkylaryl; is selected from the group consisting of a direct link, C 3 . 8 cycloalkyl, aryl.
  • E is selected from the group consisting of R 26 , -NR 26 R 27 , where R 26 , R 27 , R 28 and R 29 are independently selected from the group consisting of H, -OH, C
  • R 31 is selected from the group consisting of H, C ⁇ alkyl, aryl and C 1-4 alkylaryl, or can be taken together with R 29 to form a 5-6 membered ring; with the proviso that when E is R 26 , then K. must contain at least one N atom; Y is selected from the group consisting of H,
  • R 13 and R 14 are independently selected from the group consisting of H. C l-3 alkyl and aryl; and G is -COOR 20 , -CONR 20 R 21 , -CF 3 , -CF 2 CF 3 or a group having the formula:
  • R 22 is selected from the group consisting of H, C,. 6 alkyl, C 2 . 6 alkenyl, C 0 . 6 alkylaryl, C 2 . 6 alkenylaryl, C 0 - 6 alkylheterocyclo, C 2 . 6 alkenylheterocyclo, -CF 3 and -CF 2 CF 3 ;
  • U is -O-, -S-, -N- or -N(H ;
  • V is -O-, -S-, -N- or -N(H)-; with the proviso that at least one of U or V is -N- or -N(H>; J is -S-, -SO-, -SO 2 -, -O- or -NR 6 -, where R 6 is H, C,. 6 alkyl or benzyl; and L is selected from the group consisting of:
  • R 9 and R 10 are independently selected from the group consisting of H, C t .
  • R l substiments are H and C ⁇ -6 alkyl; more preferably H.
  • Preferred R 2 substiments are H and C 1-6 alkyl; more preferably H.
  • R 3 is preferably H.
  • the integer “m” is preferably from 0-1; more preferably 0.
  • the integer “n” is preferably from 1-4.
  • the integer “p” is preferably 3.
  • the integer “s” is preferably 0.
  • the integer “q” is preferably from 0-1.
  • Preferred "A" substiments are R 4 , -NR 4 R 5 , 7
  • R 4 is preferably H, -OH or C,. 6 alkyl; more preferably H, -OH or methyl.
  • R 3 is preferably H, -OH or C ( . 6 alkyl; more preferably H, -OH or methyl.
  • Preferred "W" substiments are C alkyl, C 5-6 cycloalkyl, aryl, or a five to ten membered heterocyclic ring system containing at least one N heteroatom; more preferably
  • Preferred "D" substiments are -CO-, -SO 2 - and -CH 2 -; more preferably -CO- and -SO2-. is preferably a direct link.
  • R 26 R 27 , R 28 , R 29 , R 30 and R 31 are independently selected from the group consisting of H and C ⁇ . 6 alkyl, more preferably H and methyl.
  • Preferred " Y" substiments are:
  • R 13 is preferably H.
  • R 14 is preferably H.
  • the "G" substi ent is preferably a group having the formula:
  • the "J" substiment is preferably -S-, -O- or -NR 6 -.
  • R 6 is preferably H.
  • the "L” substiment is preferably:
  • R 7 is preferably H.
  • R 8 is preferably H.
  • R 9 is preferably H, -O-R 11 , -COOR 11 , -CONR ⁇ R 12 or -CF 3 ; more preferably H.
  • R 10 is preferably H, -O-R 11 , -COOR 11 , -CONR u R 12 or -CF 3 ; more preferably H.
  • R" is preferably H.
  • R 12 is preferably H.
  • J and L are as defined above. This is also illustrated as a preferred group of compounds defined by the general structural formula II as: wherein: m is an integer from 0-3; n is an integer from 0-6; q is an integer from 0-2;
  • A is selected from the group consisting of R 4 , -NR 4 R D ;
  • R 4 , R ⁇ R 16 , R 17 , R 18 and R 19 are independently selected from the group consisting of H, -OH and C, ⁇ alkyl.
  • W is C 1-6 alkyl, C 3-8 cycloalkyl, C
  • L is selected from the group consisting of: a C 6 .[o heterocyclic ring system substituted by R 9 and R 10 and containing 1-4 heteroatoms selected from N, S and O; where r is an integer from 0-1 ; R 7 and R 8 are independently selected from the group consisting of H, C ⁇ . 6 alkyl, aryl, C ⁇ alkylaryl, -COOR", -CONR"R 12 , -CN and -CF 3 ; R 9 and R 10 are independently selected from the group consisting of H, C
  • A is selected from the group consisting of R 4 , -NR 4 R 5 ;
  • R 4 , R 5 , R 18 and R 19 are independently selected from the group consisting of H, -OH and C
  • W is C,. 6 alkyl, C3.gcycl0a.kyl, C ⁇ . 6 alkenyl, aryl, or a five to ten membered heterocyclic ring system containing 1-4 heteroatoms selected from the group consisting of N, O and S; with the proviso that when A is R 4 , then W must contain at least one N atom;
  • D is -CO- or -SO 2 -; and all optical isomers thereof.
  • This invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates and solvates of the compounds of formulas I, II and III.
  • the compounds of formulas I, II and III can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates and solvates of such isomers and tautomers.
  • the compounds of this invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of this invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
  • the free acid or free base form of a compound of one of the formulas above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation of freeze drying.
  • the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
  • prodrug refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug.
  • Prodrugs are variations or derivatives of the compounds of this invention which have groups cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of this invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form.
  • Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego,
  • Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative.
  • the prodrug derivatives of this invention may be combined with other features herein taught to enhance bioavailability.
  • the compounds of this invention find utility as therapeutic agents for disease states in mammals which have disorders of coagulation such as in the treatment or prevention of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation including the treatment of septic shock, deep venous thrombosis in the prevention of pulmonary embolism or the treatment of reocclusion or restenosis of reperfused coronary arteries. Further, these compounds are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex.
  • thrombotic and prothrombotic states in which the coagulation cascade is activated which include but are not limited to, deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, thromboembolic complications of surgery and peripheral arterial occlusion.
  • a method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprises administering to the mammal a therapeutically effective amount of a compound of this invention.
  • diseases treatable or preventable by the administration of compounds of this invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.
  • the compounds of the invention also find utility in a method for inhibiting the coagulation biological samples, which comprises the administration of a compound of the invention.
  • the compounds of the present invention may also be used in combination with other therapeutic or diagnostic agents.
  • the compounds of this invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin.
  • the compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects .
  • the compounds of this invention can be utilized in vivo, ordinarily in mammals such as primates, (e.g. humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro.
  • the biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the in vitro protease activity assays and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.
  • Diagnostic applications of the compounds of this invention will typically utilize formulations in the form of solutions or suspensions.
  • the compounds of this invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles.
  • Subjects in need of treatment (typically mammalian) using the compounds of this invention can be administered dosages that will provide optimal efficacy.
  • the dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
  • Formulations of the compounds of this invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations.
  • Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985).
  • Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycihe, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween, Pluronics or polyethyleneglycol.
  • buffers such as phosphate, citrate, acetate and other organic acid salts
  • antioxidants such
  • Dosage formulations of the compounds of this invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution.
  • the pH of the preparations of this invention typically will be 3-11, more preferably 5-9 and most preferably 7-8. It will be understood that use of certain of the foregoing excipients. carriers, or stabilizers will result in the formation of cyclic polypeptide salts.
  • While the preferred route of administration is by injection, other methods of administration are also anticipated such as orally, intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally, transdermally or intraperitoneally.
  • employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches.
  • the compounds of this invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available.
  • the compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • the compounds of this invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled.
  • the compounds of this invention may also be coupled with suitable polymers as targetable drug carriers.
  • suitable polymers can include polyvinylpyrrolidinone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol.
  • compounds of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
  • Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.
  • Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.
  • Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required.
  • the range of therapeutically effective dosages will be influenced by the route of administration, the therapeutic objectives and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each compound by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect.
  • the determination of effective dosage levels that is, the dosage levels necessary to achieve the desired result, will be readily determined by one skilled in the art.
  • the compounds of the invention can be administered orally or parenterally in an effective amount within the dosage range of about 0.1 to 100 mg/kg, preferably about 0.5 to 50 mg/kg and more preferably about 1 to 20 mg/kg on a regimen in a single or 2 to 4 divided daily doses and/or continuous infusion.
  • a compound or mixture of compounds of this invention is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor etc., as called for by accepted pharmaceutical practice.
  • a physiologically acceptable vehicle carrier, excipient, binder, preservative, stabilizer, dye, flavor etc.
  • the amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
  • Typical adjuvants which may be incorporated into tablets, capsules and the like are binders such as acacia, corn starch or gelatin, and excipients such as microcrystalline cellulose, disintegrating agents like corn starch or alginic acid, lubricants such as magnesium stearate, sweetening agents such as sucrose or lactose, or flavoring agents.
  • a dosage form is a capsule, in addition to the above materials it may also contain liquid carriers such as water, saline, or a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit.
  • Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
  • the compounds of the present invention may be synthesized by either solid or liquid phase methods described and referenced in standard textbooks, or by a combination of both methods. These methods are well known in the art. See, Bodanszky, "The Principles of Peptide Synthesis", Hafner, et al, Eds., Springer-Verlag, Berlin. 1984. Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.
  • Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
  • reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent.
  • the products may be further purified by column chromatography or other appropriate methods.
  • the peptide derivatives can be prepared by sequence coupling of protected Fragment-
  • Fragment-2 can be first coupled to Fragment- 1 to yield an intermediate to which Fragment-3 can then be coupled (Scheme II).
  • the protecting groups are finally removed by HF-cleavage.
  • corhpounds are purified by reversed-phase HPLC and characterized by ion- spray MS spectrometry.
  • P is a protecting group
  • P is a protecting group
  • the "D" substituent illustrated in Fragment- 1 is -CO-. Fragments similar to the structure of Fragment-1, where D is -SO , -CH 2 -, -O-CO-, -NR 15 SO 2 - or -NR 15 -CO-, can easily be synthesized by techniques such as those described in Semple, et al. , WO 95/35311.
  • R 1 and R 2 " substituents illustrated in Fragment-2 are -H. Fragments similar to the structure of Fragment-2, where R 1 is C
  • the "Y" substituent illustrated in Fragment-3 is -CO-G, where G is:
  • R 9 and R 10 are H. Fragments similar to the structure of Fragment-3, where G is: and J is -SO- or -SO 2 - can easily be synthesized by techniques that are well known in the art. Fragments where J is -O- can be synthesized by techniques illustrated in J. Am. Chem. Soc. 1 14: 1854-1863 (1992), J. Med. Chem. 38:76-85 (1995), and J. Med. Chem. 37:3492-3502 (1994). Lastly, fragments where J is -NR*-, where R is H, C,. 6 alkyl or benzyl, can be synthesized by techniques illustrated in J. Med. Chem. 37:3492-3502 (1994). All of these references are inco ⁇ orated herein by reference. Fragments similar to the structure of Fragment-3, where G is:
  • R 7 , R 8 , R 9 and R 10 are not H, can also be easily synthesized by techniques that are well known in the art.
  • Fragments similar to the structure of Fragment-3, where G is -COOR 20 , -CONR :0 R 21 , -CF 3 or -CF 2 CF 3 , can easily be synthesized by techniques that are well known in the art.
  • Fragments similar to the structure of Fragment-3. where "Y" is a boron-containing group can easily be synthesized by techniques that are well known in the art. See for example, J. Org. Chem. 60:3717-3722 ( 1995). The mechanisms for coupling the various fragments used to synthesize the compounds of the instant invention, are also well known in the art.
  • N- ⁇ -Boc-N- ⁇ -CBZ-L-ornithine (10 g, 0.027 mol) is dissolved in a solution of MeOH
  • TLC showed clean conversion to N- ⁇ -Boc-L-ornithine.
  • the crude intermediate is dissolved in dry DMF (60 mL) and heated to 50-60°C for 2.5 hours. The solvent is removed under vacuum. The oil residue is dissolved in 50 mL of CH 2 C1 2 and extracted with 50 mL of 1 N NaOH. The aqueous solution is extracted with 50 mL of CH 2 C1 2 , acidified with cooling with 50 mL of IN HCl, re-extracted with 5
  • Example 3 The compounds of Example 3 ( 1 mmol) and Example 4 ( 1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C. The solution is neutralized with DIEA ( 1 mL) followed by addition of coupling reagent BOP (1.1 mmol). The solution is stirred for 1-2 hours and HPLC analysis showed the completion of reaction. Solvent is removed by vacuum at 30°C. The residue is dissolved in a mixture of EtOAc-H 2 0 (50 mL: 10 mL). The organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgS0 4 , filtered and solvent evaporated. The oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
  • Example 4 The compound of Example 4 (1 mmol) is dissolved in 1 mL of MeOH, cooled to 0°C and treated dropwise with sat. HCl in MeOH (4 mL). The solution is stirred at 0°C for 1 hour and then warmed to room temperature and stirred for 14 hours. The solution is concentrated under vacuum to afford the compound shown above, as a clear oil which is used directly in the next example.
  • Example 9 The compounds of Example 9 (1 mmol) and 4-(Di-CBZ-guanidine)-butano ⁇ c acid (1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C. The solution is neutralized with DIEA (1 mL) followed by addition of coupling reagent BOP (1.1 mmol). The solution is stirred for 1-2 hours and HPLC analysis showed the completion of reaction. Solvent is removed by vacuum at 30°C. The residue is dissolved in a mixture of EtOAc-H 2 0 (50 mL: 10 mL) and aqueous layer is discarded. The organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO 4 , filtered and evaporated. The oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
  • Example 10 The compound of Example 10 (1 mmol) is dissolved in MeOH (1 mL) and cooled to 0°C. 5 mL of 1 N LiOH is added dropwise to the mixture and the solution is stirred at
  • Example 1 1 (1 mmol) and Example 3 (1 mmol) are dissolved in DMF (5 mL) and cooled to 0°C.
  • the solution is neutralized with DIEA ( 1 mL) followed by the addition of coupling reagent BOP (1.1 mmol).
  • the solution is stirred for 1-2 hours and HPLC analysis shows the completion of reaction.
  • Solvent is removed by vacuum at 30°C.
  • the residue is dissolved in a mixture of EtOAc-H 2 O (50 mL: 10 mL) and aqueous layer is discarded.
  • the organic layer is washed with sat. NaHCO 3 (2 X 10 mL), sat. NaCl (2 X 10 mL), dried over MgSO , filtered and evaporated.
  • the oil residue is purified by flash column on SiO 2 to give the compound shown above, as a powder.
  • EXAMPLE 14 (Determination of ICso) The compounds of the present invention are first dissolved in a buffer to give solutions containing concentrations such that assay concentrations range from 0-100 ⁇ M.
  • a synthetic chromogenic substrate In assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate would be added to a solution containing a test compound and the enzyme of interest and the residual catalytic activity of that enzyme would then be determined spectrophotometrically.
  • the IC50 of a compound is determined from the substrate turnover.
  • the IC 50 is the concentration of test compound giving 50% inhibition of the substrate turnover.
  • Preferred compounds of the invention desirably have an IC 50 of less than 500 nM in the factor Xa assay, preferably less than 200 nM, and more preferably less than 100 nM.
  • Preferred compounds of the invention desirably have an IC 50 of less than 4.0 ⁇ M in the prothrombinase assay, preferably less than 200 nM, and more preferably less than 10 nM.
  • Preferred compounds of the invention desirably have an IC 50 of greater than 1.0 ⁇ M in the thrombin assay, preferably greater than 10.0 ⁇ M, and more preferably greater than 100.0 ⁇ M.
  • Amidolytic Assays for determining protease inhibition activity Factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris HCl buffer, pH 7.5, containing 0.15 M NaCl.
  • the rates of hydrolysis of the para- nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with the test compound for 5 minutes at room temperature are determined using a Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroanilide.
  • prothrombinase inhibition assay is performed in a plasma free system with modifications to the method as described by Sinha, et al., Thromb. Res., 75:427-436
  • the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH.
  • the assay consists of a 5 minute preincubation of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Va (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 ⁇ M) in 20 mM Tris HCl buffer, pH
  • the antithrombotic efficacy of the compounds of this invention can readily be evaluated using a series of studies in rabbits, as described below. These studies are also useful in evaluating a compounds effects on hemostasis and its the hematological parameters. Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis
  • Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail.
  • a standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit.
  • a non- occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is then used as a measure of the antithrombotic activity of the compound being evaluated.
  • Test agents or control saline are administered through a marginal ear vein catheter.
  • a femoral vein catheter is used for blood sampling prior to and during steady state infusion of the compound being evaluated. Initiation of thrombus formation will begin immediately after advancement of the cotton thread apparatus into the central venous circulation.
  • the rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are then analyzed for changes in hematological and coagulation parameters.

Abstract

L'invention concerne de nouveaux composés, leurs sels et des compositions relatives auxdits composés ayant une activité contre le facteur mammifère Xa. Lesdits composés sont utiles in vitro ou in vivo pour la prévention ou le traitement de troubles de la coagulation.
PCT/US1997/018291 1996-10-11 1997-10-10 Inhibiteurs competitifs du facteur xa WO1998016523A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP51845498A JP2001504810A (ja) 1996-10-11 1997-10-10 選択的第Ｘａ因子阻害剤
AU49809/97A AU720513C (en) 1996-10-11 1997-10-10 Selective factor Xa inhibitors
CA002268281A CA2268281A1 (fr) 1996-10-11 1997-10-10 Inhibiteurs competitifs du facteur xa
EP97912697A EP0937073A2 (fr) 1996-10-11 1997-10-10 Inhibiteurs competitifs du facteur xa

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3374996P 1996-10-11 1996-10-11
US73136696A 1996-10-11 1996-10-11
US08/731,366 1997-10-10
US08/948,672 US6262047B1 (en) 1996-10-11 1997-10-10 Selective factor Xa inhibitors
US60/033,749 1997-10-10
US08/948,672 1997-10-10

Publications (3)

Publication Number Publication Date
WO1998016523A2 WO1998016523A2 (fr) 1998-04-23
WO1998016523A3 WO1998016523A3 (fr) 1998-06-18
WO1998016523A9 true WO1998016523A9 (fr) 1998-08-27

Family

ID=27364485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018291 WO1998016523A2 (fr) 1996-10-11 1997-10-10 Inhibiteurs competitifs du facteur xa

Country Status (4)

Country Link
EP (1) EP0937073A2 (fr)
JP (1) JP2001504810A (fr)
CA (1) CA2268281A1 (fr)
WO (1) WO1998016523A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
EP0975625A1 (fr) 1997-04-14 2000-02-02 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
JP2001521524A (ja) * 1997-04-14 2001-11-06 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
JP2001523226A (ja) 1997-04-14 2001-11-20 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
WO1998046627A1 (fr) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
CA2300478A1 (fr) * 1997-08-11 1999-02-18 Cor Therapeutics, Inc. Inhibiteurs selectifs du facteur xa
EP0994894A1 (fr) * 1997-08-11 2000-04-26 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
AU753842B2 (en) * 1997-08-11 2002-10-31 Millennium Pharmaceuticals, Inc. Selective factor Xa inhibitors
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
WO2000038618A2 (fr) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
US6262080B1 (en) 1998-12-31 2001-07-17 Avantis Pharmaceuticals Inc. 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
EP1156803A4 (fr) 1999-02-09 2004-03-17 Bristol Myers Squibb Co Inhibiteurs lactame de fxa et methode
JP2002536437A (ja) * 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー ＦＸａのラクタム抑制剤および方法
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
MXPA02002657A (es) 1999-09-13 2002-10-28 Dimensional Pharm Inc Inhibidores de azacicloalcanona serina proteasa.
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
CA2387493A1 (fr) 1999-10-08 2001-04-19 Lorin Andrew Thompson Amino sulfonamides de lactame utilises comme inhibiteurs de la production de proteine a.beta.
WO2001060826A2 (fr) 2000-02-17 2001-08-23 Bristol-Myers Squibb Pharma Company CARBOCYCLES ET HETEROCYCLES SUCCINOYLAMINO UTILISES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
MXPA02009729A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
BR0107532A (pt) 2000-04-03 2004-11-03 Bristol Myers Squibb Pharma Co Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica
AU2001257006A1 (en) 2000-04-11 2001-10-23 Du Pont Pharmaceuticals Company Substituted lactams as inhibitors of abeta protein production
BR0106717A (pt) 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) * 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
US7479502B2 (en) 2002-12-03 2009-01-20 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
GB0228533D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Crystalline form
BRPI1010024A2 (pt) 2009-06-05 2019-09-24 Link Medicine Corp derivados de aminopirrolidinona e uso dos mesmos
JP2023509452A (ja) 2020-01-03 2023-03-08 バーグ エルエルシー がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119466A (en) * 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
WO1997030073A1 (fr) * 1996-02-13 1997-08-21 Akzo Nobel N.V. Inhibiteurs de la serine protease

Similar Documents

Publication Publication Date Title
WO1998016523A9 (fr) Inhibiteurs competitifs du facteur xa
EP0937073A2 (fr) Inhibiteurs competitifs du facteur xa
AU4898897A (en) Selective factor xa inhibitors
EP0994892A1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa
WO1999007731A1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa
AU743544B2 (en) Selective factor Xa inhibitors
US6204268B1 (en) Selective factor Xa inhibitors
US6262047B1 (en) Selective factor Xa inhibitors
EP0994893B1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE STRUCTURE D'AZEPINONE CONDENSEE
AU741099B2 (en) Selective factor Xa inhibitors
US6369063B1 (en) Selective factor Xa inhibitors
WO1998046591A1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa
US6525076B1 (en) Selective factor Xa inhibitors
US6333321B1 (en) Selective factor Xa inhibitors
US6228854B1 (en) Selective factor Xa inhibitors
US6369080B2 (en) Selective factor Xa inhibitors
US6194435B1 (en) Lactams as selective factor Xa inhibitors
WO1998016524A1 (fr) DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa
AU720513C (en) Selective factor Xa inhibitors
US6218382B1 (en) Selective factor Xa inhibitors
AU746596B2 (en) Selective factor Xa inhibitors
AU743614B2 (en) Heterocyclic derivatives as factor Xa inhibitors
AU8826998A (en) Selective factor xa inhibitors containing a fused azepinone structure
AU8700598A (en) Selective factor xa inhibitors